亚洲肌少症工作组2019共识更新:肌少症诊断与治疗
亚洲肌少症工作组(AWGS)2019共识更新保留肌少症原定义,修订诊断流程与部分标准,提出社区与医院分设筛查路径,并引入「可能肌少症」概念以便早期生活方式干预。
要点
- 低肌力标准:握力男性<28 kg、女性<18 kg。
- 低体能标准:6米步行<1.0 m/s、SPPB≤9分或5次起坐≥12秒。
- 筛查可用小腿围(男<34 cm、女<33 cm)、SARC-F≥4或SARC-CalF≥11。
核心结论
- AWGS 2019保留肌少症原定义,修订诊断流程与部分标准,并新增「可能肌少症」以支持早期干预。
研究设计与样本
- AWGS 2019共识更新基于2014共识后亚洲研究进展制定,提出社区与医院分设诊断流程。
主要发现
- 低肌力定义为握力男性<28 kg、女性<18 kg。
- 低体能定义为6米步行<1.0 m/s、SPPB≤9分或5次起坐≥12秒。
- 身高校正肌量切点保留:DXA男性<7.0 kg/m2、女性<5.4 kg/m2;BIA男性<7.0 kg/m2、女性<5.7 kg/m2。
- 筛查指标包括小腿围男性<34 cm、女性<33 cm,SARC-F≥4,SARC-CalF≥11。
- 「可能肌少症」仅由低肌力或低体能定义,用于基层卫生或社区健康促进。
关键数值与推荐
- 握力低:男性<28 kg,女性<18 kg。
- 6米步行速度低:<1.0 m/s。
- SPPB低:≤9分。
- 5次起坐时间低:≥12秒。
- DXA肌量低:男性<7.0 kg/m2,女性<5.4 kg/m2;BIA肌量低:男性<7.0 kg/m2,女性<5.7 kg/m2。
临床怎么用
- 社区与医院均可先以小腿围、SARC-F或SARC-CalF筛查肌少症风险。
- 「可能肌少症」用于基层早期识别并启动生活方式干预。
- 生活方式干预(尤其运动与营养补充)仍为肌少症治疗主要手段。
局限性
- 以BMI校正肌量替代身高校正肌量可能更好预测不良结局,但改变推荐前需更多证据。
- 生活方式干预、营养补充或药物治疗对亚洲人的长期获益尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical and research interest in sarcopenia has burgeoned internationally, Asia included. The Asian Working Group for Sarcopenia (AWGS) 2014 consensus defined sarcopenia as "age-related loss of muscle mass, plus low muscle strength, and/or low physical performance" and specified cutoffs for each diagnostic component; research in Asia consequently flourished, prompting this update. AWGS 2019 retains the previous definition of sarcopenia but revises the diagnostic algorithm, protocols, and some criteria: low muscle strength is defined as handgrip strength <28 kg for men and <18 kg for women; criteria for low physical performance are 6-m walk <1.0 m/s, Short Physical Performance Battery score ≤9, or 5-time chair stand test ≥12 seconds. AWGS 2019 retains the original cutoffs for height-adjusted muscle mass: dual-energy X-ray absorptiometry, <7.0 kg/m2 in men and <5.4 kg/m2 in women; and bioimpedance, <7.0 kg/m2 in men and <5.7 kg/m2 in women. In addition, the AWGS 2019 update proposes separate algorithms for community vs hospital settings, which both begin by screening either calf circumference (<34 cm in men, <33 cm in women), SARC-F (≥4), or SARC-CalF (≥11), to facilitate earlier identification of people at risk for sarcopenia. Although skeletal muscle strength and mass are both still considered fundamental to a definitive clinical diagnosis, AWGS 2019 also introduces "possible sarcopenia," defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions. Although defining sarcopenia by body mass index-adjusted muscle mass instead of height-adjusted muscle mass may predict adverse outcomes better, more evidence is needed before changing current recommendations. Lifestyle interventions, especially exercise and nutritional supplementation, prevail as mainstays of treatment. Further research is needed to investigate potential long-term benefits of lifestyle interventions, nutritional supplements, or pharmacotherapy for sarcopenia in Asians.
引用
- Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020. PMID: 32033882. doi:10.1016/j.jamda.2019.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。